AI Article Synopsis
- 5-fluorouracil is widely used in cancer treatment but can cause various side effects, particularly affecting bone marrow, skin, and mucous membranes.
- Cardiotoxicity is a serious and unpredictable side effect that can lead to life-threatening conditions such as angina, arrhythmias, and heart failure.
- This discussion includes typical symptoms, treatment options, patient prognosis, and management recommendations for those undergoing treatment with 5-fluorouracil.
Article Abstract
Treatment with 5-fluorouracil is common in oncological patients. Side effects on bone marrow, skin, and mucous membranes have been reported. Cardiotoxicity, which is less predictable, can be life-threatening. Manifestations include angina, arrhythmias, infarction, heart failure and cardiogenic shock. The toxic mechanisms that might be involved have been much discussed but have not yet been clearly established. Current evidence supports the possibility of a metabolic effect in common with the cascade secondary to ischemia due to coronary disease. Based on a case report, we discuss the usual clinical presentation, treatment and prognosis. Finally we make recommendations for managing patients being treated with 5-fluorouracil.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0300-8932(02)76696-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of glyceryl trinitrate in reducing cardiac events when given concomitantly with capecitabine for at least 3 months in various tumors.
Pak J Pharm Sci
September 2024
Department of Oncologist, Hameed Latif Hospital, Lahore, Pakistan.
Capecitabine is an oral pro-drug of 5-flourouracil used in treatment of different cancers. It has cardiotoxicity incidence of 3-35%, which can be significant enough to cause myocardial infarction. To evaluate the efficacy of glyceryl trinitrate in reducing cardiac events when given concomitantly with capecitabine for at least 3 months in various tumors.
View Article and Find Full Text PDFNeoadjuvant Chemotherapy: Friend or Foe.
Maedica (Bucur)
June 2024
Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Introduction: Most breast cancers require neoadjuvant chemotherapy and the response to primary systemic therapy (PST) is crucial for deciding on the surgical technique and predicting patient outcomes. However, chemotherapy also brings numerous side effects, with cardiovascular issues being some of the most significant, common and challenging to manage.
Case Presentation: We present the case of a 71-year-old woman diagnosed with stage T2N1M0 Luminal B breast cancer.
Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator.
ESC Heart Fail
October 2024
Barts Heart Centre, Barts Health NHS Trust, London, UK.
Aims: Fluoropyrimidine chemotherapy is important for treatment of many solid tumours but is associated with cardiotoxicity. The relationship of fluoropyrimidine-associated cardiotoxicity (FAC) with conventional cardiovascular (CV) risk factors is poorly understood, and standard cardiovascular risk scores are not validated in this context.
Methods And Results: Single-centre retrospective study of patients treated with fluoropyrimidine chemotherapy using electronic health records for cardiovascular risk factors (and calculation of QRISK3 score), cancer treatment, and clinical outcomes.
Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment.
Cardiovasc Toxicol
February 2024
Department of Internal Medicine, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Advancements in cancer treatments have improved survival rates but have also led to increased cardiotoxicities, which can cause adverse cardiovascular events or worsen pre-existing conditions. Herein, cardiotoxicity is a severe adverse effect of 5-fluorouracil (5-FU) therapy in cancer patients, with reported incidence rates ranging from 1 to 20%. Some studies have also suggested subclinical effects and there are reports which have documented instances of cardiac arrest or sudden death during 5-FU treatment, highlighting the importance of timely management of cardiovascular symptoms.
View Article and Find Full Text PDFThe puzzling clinical presentation of fluoropyrimidines cardiotoxicity.
Front Cardiovasc Med
September 2022
Department of Cardiology, Azienda Sanitaria Friuli Occidentale, ASFO, Pordenone, Italy.
The cardiotoxicity of fluoropyrimidines (FP) [5-Fluorouracil and Capecitabine] is often reported as acute cardiac ischemia with rest typical angina, signs of ischemia at electrocardiogram (ECG), and ventricular kinetics abnormalities. However, silent ischemia, effort-related toxicity, and ventricular arrhythmias (VA) have been also described. The aim of this study is to report a consecutive series of 115 patients with FP cardiotoxicity observed in a single center both within clinical prospective studies and during the clinical routine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!